SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.
Investors are reacting to the departure of CSL's CFO, Joy Linton, amid a major restructuring that includes workforce cuts and the spin-off of its Seqirus vaccines business, leading to fluctuations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback